Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours

被引：0
|
作者：
Peng Yuan
Jianzhong Shentu
Jianming Xu
Wendy Burke
Kate Hsu
Maria Learoyd
Min Zhu
Binghe Xu
机构：
[1] Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC),National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center
[2] The First Affiliated Hospital of Zhejiang University,Research Center for Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease
[3] Academy of Military Medical Sciences,Affiliated Hospital Cancer Center, The 307th Hospital of Chinese People’s Liberation Army
[4] Covance Clinical Research Unit,undefined
[5] AstraZeneca,undefined
[6] AstraZeneca,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 83卷
关键词：
Chinese patients; Olaparib; Paclitaxel; PARP inhibitor; Pharmacokinetics; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：963 / 974
页数：11
相关论文
共 50 条
  • [21] Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours
    Vinodh R. Nannan Panday
    Ronald de Wit
    Jan H. Schornagel
    Margaret Schot
    Hilde Rosing
    Jan Lieverst
    Wim W. ten Bokkel Huinink
    Jan H. M. Schellens
    Jos H. Beijnen
    Cancer Chemotherapy and Pharmacology, 1999, 44 : 349 - 353
  • [22] Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours
    Panday, VRN
    de Wit, R
    Schornagel, JH
    Schot, M
    Rosing, H
    Lieverst, J
    Huinink, WWT
    Schellens, JHM
    Beijnen, JH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (04) : 349 - 353
  • [23] Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours
    Androulakis, N
    Kouroussis, C
    Mavroudis, D
    Kakolyris, S
    Souglakos, J
    Agelaki, S
    Kalbakis, K
    Malas, K
    Pallis, A
    Samonis, G
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (15) : 1992 - 1997
  • [24] Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours
    Hollebecque, A.
    Bahleda, R.
    Faivre, L.
    Adam, J.
    Poinsignon, V.
    Paci, A.
    Gomez-Roca, C.
    Thery, J. C.
    Le Deley, M. C.
    Varga, A.
    Gazzah, A.
    Ileana, E.
    Gharib, M.
    Angevin, E.
    Malekzadeh, K.
    Massard, C.
    Soria, J. C.
    Spano, J. P.
    EUROPEAN JOURNAL OF CANCER, 2017, 81 : 81 - 89
  • [25] Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
    de Jonge, M. J. A.
    Dumez, H.
    Kitzen, J. J. E. M.
    Beuselinck, B.
    Verweij, J.
    Courtney, R.
    Battista, A.
    Brega, N.
    Schoffski, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (09) : 1328 - 1335
  • [26] A Phase Ib Study of Safety and Pharmacokinetics of Ramucirumab in Combination With Paclitaxel in Patients With Advanced Gastric Adenocarcinomas
    Ueda, Shinya
    Satoh, Taroh
    Gotoh, Masahiro
    Gao, Ling
    Do, Toshihiko
    ONCOLOGIST, 2015, 20 (05): : 493 - 494
  • [27] A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours
    Angel Izquierdo, Miguel
    Garcia, Margarita
    Luis Ponton, Jose
    Martinez, Marisa
    Valenti, Vicente
    Navarro, Matilde
    Gil, Miguel
    Cardenal, Felipe
    Mesia, Ricard
    Perez, Xavier
    Salazar, Ramon
    Ramon Germa-Lluch, Josep
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (12) : 1789 - 1796
  • [28] Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study
    Dieras, V.
    Lortholary, A.
    Laurence, V.
    Delva, R.
    Girre, V.
    Livartowski, A.
    Assadourian, S.
    Semiond, D.
    Pierga, J. Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) : 25 - 34
  • [29] A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
    O A Khan
    M Gore
    P Lorigan
    J Stone
    A Greystoke
    W Burke
    J Carmichael
    A J Watson
    G McGown
    M Thorncroft
    G P Margison
    R Califano
    J Larkin
    S Wellman
    M R Middleton
    British Journal of Cancer, 2011, 104 : 750 - 755
  • [30] Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
    Martin, L. P.
    Kozloff, M. F.
    Herbst, R. S.
    Samuel, T. A.
    Kim, S.
    Rosbrook, B.
    Tortorici, M.
    Chen, Y.
    Tarazi, J.
    Olszanski, A. J.
    Rado, T.
    Starr, A.
    Cohen, R. B.
    BRITISH JOURNAL OF CANCER, 2012, 107 (08) : 1268 - 1276
12345